ACBI1 是一种基于 PROTAC 的有效 BAF ATPase 亚基 SMARCA2 和 SMARCA4 以及 PBAF 复合体成员 PBRM1 的降解剂。它表现出抗癌活性并诱导细胞凋亡,对 SMARCA2、SMARCA4 和 PBRM1 的 DC50 值分别为 6 nM、11 nM 和 32 nM。
HazMat Fee + There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.
| Type | HazMat fee for 500 gram (Estimated) |
| Excepted Quantity | USD 0.00 |
| Limited Quantity | USD 15-60 |
| Inaccessible (Haz class 6.1), Domestic | USD 80+ |
| Inaccessible (Haz class 6.1), International | USD 150+ |
| Accessible (Haz class 3, 4, 5 or 8), Domestic | USD 100+ |
| Accessible (Haz class 3, 4, 5 or 8), International | USD 200+ |


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | BET ↓ ↑ | bromodomain ↓ ↑ | BRPF ↓ ↑ | CBP/beta-catenin ↓ ↑ | p300/CBP ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MS436 |
++
BRD4 (1), Ki: <0.085 μM BRD4 (2), Ki: 0.34 μM |
99%+ | |||||||||||||||||
| CPI-203 |
+++
BRD4, IC50: 37 nM |
98+% | |||||||||||||||||
| GSK1324726A |
+++
BRD2, IC50: 31 nM BRD4, IC50: 22 nM |
99%+ | |||||||||||||||||
| PFI-1 |
++
BRD2, IC50: 98 nM BRD4, IC50: 0.22 μM |
98% | |||||||||||||||||
| Apabetalone |
+
BD2, IC50: 0.51 μM |
99% | |||||||||||||||||
| (+)-JQ1 |
+++
BRD4 (1), IC50: 77 nM BRD4 (2), IC50: 33 nM |
98% | |||||||||||||||||
| I-BET151 |
+
BRD3, IC50: 0.25 μM BRD4, IC50: 0.5 μM |
98% | |||||||||||||||||
| Molibresib |
+++
BET proteins, IC50: 35 nM |
99%+ | |||||||||||||||||
| I-BRD9 |
+++
BRD4, pIC50: 5.3 BRD9, pIC50: 7.3 |
99%+ | |||||||||||||||||
| BI-7273 |
++++
BRD7, IC50: 117 nM BRD9, IC50: 19 nM |
97% | |||||||||||||||||
| Pelabresib |
+++
BRD4-BD1, IC50: 39 nM |
98% | |||||||||||||||||
| ARV-825 |
+++
BRD4 BD1, Kd: 90 nM BRD4 BD2, Kd: 28 nM |
99%+ | |||||||||||||||||
| Birabresib | 99%+ | ||||||||||||||||||
| BI 2536 |
+++
BRD4, Kd: 37 nM |
c-Myc | 99%+ | ||||||||||||||||
| Bromosporine |
++
BRD2, IC50: 0.29 μM BRD9, IC50: 0.122 μM |
++++
CECR2, IC50: 17 nM |
99%+ | ||||||||||||||||
| XMD8-92 |
++
BRD4 (1), Kd: 170 nM |
99%+ | |||||||||||||||||
| Mivebresib | ✔ | 99%+ | |||||||||||||||||
| BI-9564 |
++++
BRD9, Kd: 5.9 nM BRD7, Kd: 73 nM |
++
CECR2, Kd: 77 nM |
98% | ||||||||||||||||
| AZD5153 6-Hydroxy-2-naphthoic acid |
++++
FL-BRD4, IC50: 5 nM |
99%+ | |||||||||||||||||
| PLX51107 |
++++
BRD4 BD2, Kd: 1.7 nM BRD3 BD1, Kd: 2.1 nM |
99%+ | |||||||||||||||||
| FL-411 |
+
BRD4(1), IC50: 0.43 μM |
99%+ | |||||||||||||||||
| ABBV-744 | ✔ | 99%+ | |||||||||||||||||
| dBET6 |
++++
BRD4, IC50: 14 nM |
99%+ | |||||||||||||||||
| dBET1 |
++++
BRD4, IC50: 20 nM |
99%+ | |||||||||||||||||
| MZ1 |
++++
Brd3(BD2), Kd: 13 nM Brd2(BD2), Kd: 62 nM |
99%+ | |||||||||||||||||
| dBET57 |
+
BRD4BD1, DC50: 500 nM |
99%+ | |||||||||||||||||
| SF2523 |
+
BRD4, IC50: 241 nM |
DNA-PK | 99%+ | ||||||||||||||||
| INCB054329 |
++++
BRD3-BD1, IC50: 9 nM BRD4-BD1, IC50: 119 nM |
99% | |||||||||||||||||
| INCB-057643 | ✔ | 99%+ | |||||||||||||||||
| (E/Z)-ZL0420 |
+++
BRD4 BD1, IC50: 27 nM BRD4 BD2, IC50: 32 nM |
99%+ | |||||||||||||||||
| BMS-986158 | ✔ | 99% | |||||||||||||||||
| BRD4 Inhibitor-10 |
++++
BRD4-BD1, IC50: 5 nM BRD4-BD2, IC50: 41 nM |
97% | |||||||||||||||||
| A1874 | ✔ | 99%+ | |||||||||||||||||
| Y06036 |
++
BRD4 (1), Kd: 82 nM |
99%+ | |||||||||||||||||
| Alobresib | ✔ | NF-κB | 95% | ||||||||||||||||
| ODM-207 | ✔ | 98% | |||||||||||||||||
| GSK778 |
+++
BRD2-BD1, IC50: 75nM BRD4-BD1, IC50: 143 nM |
97% | |||||||||||||||||
| SRX3207 |
+
BRD42, IC50: 3070 nM BRD41, IC50: 3070 nM |
Syk | 98% | ||||||||||||||||
| GSK046 |
+++
BRD3BD2, IC50: 98 nM BRD4BD2, IC50: 214 nM |
98% | |||||||||||||||||
| GSK620 | ✔ | 97% | |||||||||||||||||
| Trotabresib | ✔ | 99% | |||||||||||||||||
| NHWD-870 | ✔ | 98% | |||||||||||||||||
| CFT8634 |
++++
BRD9, DC50: 3 nM |
98% | |||||||||||||||||
| GSK2801 |
++
BAZ2A, Kd: 257 nM BAZ2B, Kd: 136 nM |
99%+ | |||||||||||||||||
| KG-501 | ✔ | 99%+ | |||||||||||||||||
| UNC 669 |
+
L3MBTL3, IC50: 35 μM L3MBTL4, IC50: 6 μM |
99% | |||||||||||||||||
| PFI-3 |
+++
SMARCA2A, Kd: 72 nM SMARCA4, Kd: 55 nM |
99%+ | |||||||||||||||||
| UNC1215 |
+++
L3MBTL3, IC50: 120 nM L3MBTL3- D274A, IC50: 3.5 μM |
99%+ | |||||||||||||||||
| EED226 |
++
EED, Kd: 82 nM PRC2, Kd: 114 nM |
99%+ | |||||||||||||||||
| BRD9539 | ✔ | 98% | |||||||||||||||||
| UNC926 |
+
L3MBTL1, Kd: 3.9 μM |
99% | |||||||||||||||||
| 666-15 |
++
CREB, IC50: 81 nM |
99%+ | |||||||||||||||||
| UNC6852 |
+
EED, IC50: 247 nM |
98% | |||||||||||||||||
| BAZ1A-IN-1 |
+
BAZ1A, Kd: 0.52 μM |
99%+ | |||||||||||||||||
| PFI-4 |
++
BRPF2, IC50: 7.9 μM BRPF1, IC50: 80 nM |
99%+ | |||||||||||||||||
| OF-1 |
++
BRPF1B, Kd: 100 nM BRPF2, Kd: 500 nM |
99%+ | |||||||||||||||||
| GSK-5959 |
++
BRPF3, pIC50: 7.1 BRPF2, pIC50: 5.2 |
99% | |||||||||||||||||
| GSK6853 |
++++
BRPF1, pIC50: 8.1 |
99%+ | |||||||||||||||||
| NI-42 |
++++
BRPF3, IC50: 260 nM BRPF1, IC50: 48 nM |
99%+ | |||||||||||||||||
| E-7386 |
+++
CBP/beta-catenin, IC50: 0.0484 μM |
99% | |||||||||||||||||
| I-CBP112 |
++
p300, Kd: 167 nM CBP, Kd: 151 nM |
98+% | |||||||||||||||||
| Histone Acetyltransferase Inhibitor II |
+
p300, IC50: 5 μM |
98% | |||||||||||||||||
| C646 |
+
p300/CBP, Ki: 400 nM |
99%+ | |||||||||||||||||
| Anacardic Acid |
+
p300/CBP, IC50: 8.5 μM PCAF, IC50: 5 μM |
99%+ | |||||||||||||||||
| SGC-CBP30 |
++++
EP300, IC50: 38 nM CREBBP, IC50: 21 nM |
99%+ | |||||||||||||||||
| Nordihydroguaiaretic acid | ✔ | IGF-1R,HER2 | 99%+ | ||||||||||||||||
| Curcumin |
+
p300, IC50: ~25 μM |
Nrf2,Ferroptosis,NF-κB | 98% | ||||||||||||||||
| CPI-637 |
+++
CBP, IC50: 0.03 μM EP300, IC50: 0.051 μM |
99%+ | |||||||||||||||||
| Foscenvivint | ✔ | β-catenin | 99%+ | ||||||||||||||||
| A-485 |
++
p300 HAT, IC50: 0.06 μM |
99%+ | |||||||||||||||||
| GNE-781 |
+
BRD4(1), IC50: 5100 nM |
++++
CBP, IC50: 0.94 nM |
99% | ||||||||||||||||
| NEO2734 |
+++
BET, IC50: <30 nM |
+++
p300/CBP, IC50: <30 nM |
99%+ | ||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 描述 | ACBI1 is a potent and synergistic degrader of SMARCA2, SMARCA4, and PBRM1 with DC50 values of 6, 11, and 32 nM, respectively. It functions as a PROTAC degrader, exhibiting anti-proliferative activity and inducing apoptosis[1]. |
| 体外研究 | ACBI1 (1-10000 nM; 3-7 days) exhibits anti-proliferative activity[1]. ACBI1 (0.3 µM; 100 h) triggers apoptosis in SK-MEL-5 cells[1]. ACBI1 comprises a bromodomain ligand, a linker, and the E3 ubiquitin ligase von Hippel-Lindau[1]. |
| Concentration | Treated Time | Description | References | |
| MV-4-11 cells | 32 nM | 18 h | Degradation of PBRM1 | Nat Chem Biol. 2019 Jul;15(7):672-680. |
| MV-4-11 cells | 11 nM | 18 h | Degradation of SMARCA4 | Nat Chem Biol. 2019 Jul;15(7):672-680. |
| MV-4-11 cells | 6 nM | 18 h | Degradation of SMARCA2 | Nat Chem Biol. 2019 Jul;15(7):672-680. |
| Rh30 | 200 nM | 24-48 hours | To evaluate the effect of ACBI1 on PBRM1 protein expression | Oncogene. 2022 Mar;41(11):1647-1656. |
| NCI-H1568 cells | 15.6 nM | 18 h | Degradation of PBRM1 | Nat Chem Biol. 2019 Jul;15(7):672-680. |
| NCI-H1568 cells | 3.3 nM | 18 h | Degradation of SMARCA2 | Nat Chem Biol. 2019 Jul;15(7):672-680. |
| Rh30 | 50 nM | 3 days | To evaluate the effect of ACBI1 on SMARCA4 and SMARCA2 protein expression | Oncogene. 2022 Mar;41(11):1647-1656. |
| HEK293T cells | 500 nM | 72 hours | To evaluate the effect of ACBI1 on SMARCA4 protein levels in HEK293T cells, results showed that ACBI1 treatment led to a reduction in SMARCA4 protein levels. | Nat Struct Mol Biol. 2023 Nov;30(11):1640-1652. |
| HS-SY-II cells | 500 nM | 72 hours | To evaluate the effect of ACBI1 on SMARCA4 protein levels in HS-SY-II cells, results showed that ACBI1 treatment led to a reduction in SMARCA4 protein levels. | Nat Struct Mol Biol. 2023 Nov;30(11):1640-1652. |
| G401 cells | 250 nM | 1 hour to 24 hours | To evaluate the effect of ACBI1 on BRG1 and PBRM1 protein levels, results showed that ACBI1 rapidly reduced BRG1 and PBRM1 levels. | Oncogenesis. 2022 Jun 1;11(1):30. |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
1.07mL 0.21mL 0.11mL |
5.34mL 1.07mL 0.53mL |
10.68mL 2.14mL 1.07mL |
|
| CAS号 | 2375564-55-7 |
| 分子式 | C49H58FN9O7S |
| 分子量 | 936.1 |
| SMILES Code | CC(N=CS1)=C1C2=CC=C(CNC([C@@H]3C[C@@H](O)CN3C([C@H](C(C)(C)C)NC(C4(CC4)F)=O)=O)=O)C(OCCOC5=CC=C(CN6CCN(C7=CC(C8=C(O)C=CC=C8)=NN=C7N)CC6)C=C5)=C2 |
| MDL No. | MFCD32689497 |
| 别名 | |
| 运输 | 蓝冰 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Keep in dark place, inert atmosphere, store in freezer, under -20°C |
| 溶解方案 |
DMSO: 105 mg/mL(112.17 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1